The Exploration of Micrornas Expression Profiling in Pancreatic Cancer
Pei Li,Qinhong Xu,Wanxing Duan,Liang Han,Zheng Wang
DOI: https://doi.org/10.1093/annonc/mdt203.42
IF: 51.769
2013-01-01
Annals of Oncology
Abstract:Background: MicroRNAs (miRNAs), small non-coding, cellular RNAs (17-27 bp) that post-transcriptionally regulate gene expression by inducing the degradation or translational repression of target mRNAs, function as oncogenes and tumor suppressors via binding target genes. Their expression levels are associated with a variety of cancers. This study to explore the miRNA expression differences between pancreatic cancer tissue and adjacent tissue, and their impact on the biological characteristics of pancreatic cancer cells. Lay the foundation for further study of the molecular mechanisms of miRNAs in pancreatic cancer development.Methods: Differential expression of 13 miRNAs (miR-9, miR-21, miR-103, miR-106a, miR-139, miR-143, miR-145, miR-185, miR-195, miR-221, miR-222, miR-381, miR-638) was analyzed by real time RT-PCR. All 13 miRNAs chosen for the test are based on their potential functions related to cancer biology, cell development and apoptosis. The expression of miRNAs for pancreatic cancer tissue samples was normalized to U6 RNA and compared with those in the relatively para-carcinoma tissue. MiRNA-106a mimics and inhibitors were transfected in Panc-01 using Lipofectamine 2000. The rate of cell proliferation and apoptosis changes were detected with MTT and flow cytometry respectively.Results: The results show miRNA-21/106a/222 were up-regulated in pancreatic cancer. MiRNA-21 was up-regulated in 85.71% patients by an average of 42.01 times. MiRNA-106a was up-regulated in 90.47% patients by an average of 4.44 times, MiRNA-222 was 76.19% and 6.81. Cells transfected with miR-106a inhibitor proliferated at a significantly lower rate than the mimics group as evaluated by MTT assay. By Annexin V analysis, the apoptotic cells were significantly increased in cells transfected with miR-106a inhibitor as compared to cells transfected with mimics.Conclusion: Pancreatic cancer has a miRNA-specific expression profile. The miRNAs were differentially expressed between pancreatic cancer tissue and adjacent tissue. MiRNA-106a was highly expressed in pancreatic cancer, indicated it has positive aspect in occurrence and development of pancreatic cancer. The treatment of inhibiting miRNA-106a may be a efficient approach to treat pancreatic cancer. Background: MicroRNAs (miRNAs), small non-coding, cellular RNAs (17-27 bp) that post-transcriptionally regulate gene expression by inducing the degradation or translational repression of target mRNAs, function as oncogenes and tumor suppressors via binding target genes. Their expression levels are associated with a variety of cancers. This study to explore the miRNA expression differences between pancreatic cancer tissue and adjacent tissue, and their impact on the biological characteristics of pancreatic cancer cells. Lay the foundation for further study of the molecular mechanisms of miRNAs in pancreatic cancer development. Methods: Differential expression of 13 miRNAs (miR-9, miR-21, miR-103, miR-106a, miR-139, miR-143, miR-145, miR-185, miR-195, miR-221, miR-222, miR-381, miR-638) was analyzed by real time RT-PCR. All 13 miRNAs chosen for the test are based on their potential functions related to cancer biology, cell development and apoptosis. The expression of miRNAs for pancreatic cancer tissue samples was normalized to U6 RNA and compared with those in the relatively para-carcinoma tissue. MiRNA-106a mimics and inhibitors were transfected in Panc-01 using Lipofectamine 2000. The rate of cell proliferation and apoptosis changes were detected with MTT and flow cytometry respectively. Results: The results show miRNA-21/106a/222 were up-regulated in pancreatic cancer. MiRNA-21 was up-regulated in 85.71% patients by an average of 42.01 times. MiRNA-106a was up-regulated in 90.47% patients by an average of 4.44 times, MiRNA-222 was 76.19% and 6.81. Cells transfected with miR-106a inhibitor proliferated at a significantly lower rate than the mimics group as evaluated by MTT assay. By Annexin V analysis, the apoptotic cells were significantly increased in cells transfected with miR-106a inhibitor as compared to cells transfected with mimics. Conclusion: Pancreatic cancer has a miRNA-specific expression profile. The miRNAs were differentially expressed between pancreatic cancer tissue and adjacent tissue. MiRNA-106a was highly expressed in pancreatic cancer, indicated it has positive aspect in occurrence and development of pancreatic cancer. The treatment of inhibiting miRNA-106a may be a efficient approach to treat pancreatic cancer.